
    
      ZPU-003 EXT is a 2-year extension study of ZPU-003 (NCT00882258). The purpose of the study is
      to determine the continued safety and efficacy of Proellex in women who have previously
      completed the double-blind portion of the study. The desired primary efficacy outcome will be
      a changes in vaginal bleeding from baseline to 14 months and 17 months on study drug. The
      total duration of the study is up to 24 months including transition times, off drug
      intervals, and follow-up visits). It is expected that over a 16 week on drug interval menses
      will subside and return after a 4-8 week off drug interval (ODI).
    
  